What is a stock summary page? Click here for an overview.
Business Description
GenMont Biotech Inc
NAICS : 541711
SIC : 8731
ISIN : TW0003164000
Description
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.59 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.85 | |||||
| Interest Coverage | 10.79 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 5.55 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.4 | |||||
| 3-Year EBITDA Growth Rate | -4.6 | |||||
| 3-Year EPS without NRI Growth Rate | -21 | |||||
| 3-Year Book Growth Rate | -0.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.79 | |||||
| 9-Day RSI | 39 | |||||
| 14-Day RSI | 45.24 | |||||
| 3-1 Month Momentum % | 0.74 | |||||
| 6-1 Month Momentum % | -11.16 | |||||
| 12-1 Month Momentum % | -9.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.87 | |||||
| Quick Ratio | 3.31 | |||||
| Cash Ratio | 3.04 | |||||
| Days Inventory | 218.12 | |||||
| Days Sales Outstanding | 31.71 | |||||
| Days Payable | 17.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.77 | |||||
| Dividend Payout Ratio | 0.76 | |||||
| 3-Year Dividend Growth Rate | -10.6 | |||||
| Forward Dividend Yield % | 3.77 | |||||
| 5-Year Yield-on-Cost % | 1.69 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 0.17 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.81 | |||||
| Operating Margin % | 10.41 | |||||
| Net Margin % | 14.86 | |||||
| FCF Margin % | 20.67 | |||||
| ROE % | 4.28 | |||||
| ROA % | 3.38 | |||||
| ROIC % | 2.37 | |||||
| 3-Year ROIIC % | -100.7 | |||||
| ROC (Joel Greenblatt) % | 6.38 | |||||
| ROCE % | 4.42 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 32.12 | |||||
| PE Ratio without NRI | 32.27 | |||||
| Shiller PE Ratio | 74.41 | |||||
| Price-to-Owner-Earnings | 22.77 | |||||
| PEG Ratio | 7.17 | |||||
| PS Ratio | 4.71 | |||||
| PB Ratio | 1.36 | |||||
| Price-to-Tangible-Book | 1.36 | |||||
| Price-to-Free-Cash-Flow | 23.12 | |||||
| Price-to-Operating-Cash-Flow | 14.77 | |||||
| EV-to-EBIT | 24.18 | |||||
| EV-to-EBITDA | 11.82 | |||||
| EV-to-Revenue | 4.29 | |||||
| EV-to-FCF | 20.77 | |||||
| Price-to-GF-Value | 0.84 | |||||
| Price-to-Projected-FCF | 2.64 | |||||
| Price-to-Median-PS-Value | 0.84 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.52 | |||||
| Price-to-Graham-Number | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 9.91 | |||||
| Price-to-Net-Cash | 26.5 | |||||
| Earnings Yield (Greenblatt) % | 4.14 | |||||
| FCF Yield % | 4.34 | |||||
| Forward Rate of Return (Yacktman) % | 9.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GenMont Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 385.373 | ||
| EPS (TTM) (NT$) | 0.66 | ||
| Beta | -0.07 | ||
| 3-Year Sharpe Ratio | -0.52 | ||
| 3-Year Sortino Ratio | -0.62 | ||
| Volatility % | 12.58 | ||
| 14-Day RSI | 45.24 | ||
| 14-Day ATR (NT$) | 0.607323 | ||
| 20-Day SMA (NT$) | 22.0575 | ||
| 12-1 Month Momentum % | -9.98 | ||
| 52-Week Range (NT$) | 19.2 - 25.35 | ||
| Shares Outstanding (Mil) | 86.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GenMont Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GenMont Biotech Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
GenMont Biotech Inc Frequently Asked Questions
What is GenMont Biotech Inc(TPE:3164)'s stock price today?
The current price of TPE:3164 is NT$21.20. The 52 week high of TPE:3164 is NT$25.35 and 52 week low is NT$19.20.
When is next earnings date of GenMont Biotech Inc(TPE:3164)?
The next earnings date of GenMont Biotech Inc(TPE:3164) is .
Does GenMont Biotech Inc(TPE:3164) pay dividends? If so, how much?
The Dividend Yield %  of GenMont Biotech Inc(TPE:3164) is 3.77% (As of Today), Highest Dividend Payout Ratio of GenMont Biotech Inc(TPE:3164) was 2.37. The lowest was 0.53. And the median was 1.44. The  Forward Dividend Yield % of GenMont Biotech Inc(TPE:3164) is 3.77%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers